|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
585,690,000 |
Market
Cap: |
178.65(B) |
Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
52
Week Range: |
$217.36 - $324.56 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 499 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
Total People Sold |
1 |
1 |
3 |
6 |
Total Sell Transactions |
1 |
1 |
4 |
8 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2020-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
50,656 |
|
- |
|
Jacks Tyler |
Director |
|
2020-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
846 |
11,302 |
|
- |
|
Gordon Murdo |
EVP Global Commercial Ops |
|
2020-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,469 |
37,873 |
|
- |
|
Garland Greg C. |
Director |
|
2020-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
846 |
9,024 |
|
- |
|
Kullman Ellen Jamison |
Director |
|
2020-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
977 |
6,380 |
|
- |
|
Austin Wanda M |
Director |
|
2020-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
846 |
3,194 |
|
- |
|
Piacquad David |
SVP, Business Development |
|
2020-05-03 |
4 |
D |
$230.98 |
$31,413 |
D/D |
(136) |
41,504 |
|
- |
|
Patton Cynthia M |
SVP & CCO |
|
2020-05-03 |
4 |
D |
$230.98 |
$29,334 |
D/D |
(127) |
24,075 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2020-05-03 |
4 |
D |
$230.98 |
$637,274 |
D/D |
(2,759) |
531,782 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2020-05-03 |
4 |
D |
$230.98 |
$42,731 |
D/D |
(185) |
37,939 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2020-05-03 |
4 |
D |
$230.98 |
$128,194 |
D/D |
(555) |
47,356 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2020-05-03 |
4 |
D |
$230.98 |
$44,810 |
D/D |
(194) |
43,049 |
|
- |
|
Piacquad David |
SVP, Business Development |
|
2020-05-01 |
4 |
D |
$239.22 |
$29,424 |
D/D |
(123) |
41,640 |
|
- |
|
Johnston Lori A |
EVP, HR |
|
2020-05-01 |
4 |
D |
$239.22 |
$80,139 |
D/D |
(335) |
29,307 |
|
- |
|
Patton Cynthia M |
SVP & CCO |
|
2020-05-01 |
4 |
D |
$239.22 |
$27,510 |
D/D |
(115) |
24,202 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2020-05-01 |
4 |
D |
$239.22 |
$654,745 |
D/D |
(2,737) |
534,541 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2020-05-01 |
4 |
D |
$239.22 |
$250,224 |
D/D |
(1,046) |
38,124 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2020-05-01 |
4 |
D |
$239.22 |
$131,332 |
D/D |
(549) |
47,911 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2020-05-01 |
4 |
D |
$239.22 |
$141,857 |
D/D |
(593) |
43,243 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2020-04-27 |
4 |
D |
$236.28 |
$39,695 |
D/D |
(168) |
39,170 |
|
- |
|
Patton Cynthia M |
SVP & CCO |
|
2020-04-27 |
4 |
D |
$236.28 |
$24,101 |
D/D |
(102) |
24,317 |
|
- |
|
Piacquad David |
SVP, Business Development |
|
2020-04-27 |
4 |
D |
$236.28 |
$27,408 |
D/D |
(116) |
41,763 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2020-04-27 |
4 |
D |
$236.28 |
$124,283 |
D/D |
(526) |
43,836 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2020-04-27 |
4 |
D |
$236.28 |
$129,481 |
D/D |
(548) |
48,460 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2020-04-27 |
4 |
D |
$236.28 |
$600,860 |
D/D |
(2,543) |
537,278 |
|
- |
|
2206 Records found
|
|
Page 17 of 89 |
|
|